Comparison tool
Follistatin vs Desmopressin side-by-side
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Comparison tool
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Selected (2/4)
Share this peptide comparison
| Property | Follistatin | Desmopressin |
|---|---|---|
| Category | Hormonal | Hormonal |
| Also known as | FST | DDAVP, Stimate, Minirin |
| FDA approved | No | Yes |
| Clinical status | Investigational - Gene therapy trials Not applicable | FDA Approved - Multiple indications
|
| What to expect | Muscle growth, myostatin inhibition, body composition | Bedwetting, diabetes insipidus, bleeding disorders |
| How it works | Follistatin is presented as a protein that interacts with myostatin/GDF-8 and related activin-family signals. The source describes this binding as preventing those ligands from engaging activin type II receptors, which may reduce signaling pathways that normally limit skeletal-muscle growth. Because it can affect more than one TGF-beta family ligand, its biological effects may be broader than a myostatin-only blocker. | Desmopressin is described as a V2-selective vasopressin receptor agonist. In renal collecting ducts, V2 activation raises intracellular signaling that moves aquaporin water channels into place, allowing more water to be reabsorbed and producing smaller volumes of more concentrated urine. The source also notes that desmopressin has much less V1-mediated blood-vessel constriction than vasopressin. In endothelial tissue, V2 activity can increase release of stored von Willebrand factor and factor VIII, linking the same receptor system to hemostatic effects in selected bleeding disorders. |
| Typical dosing | Limited community data available · See research protocols | Limited community data available · See research protocols |
| Research dosing | 100-300 mcg daily · Daily · Variable protocols · Subcutaneous injection | 10-40 mcg intranasal · Varies by condition · Intranasal, oral, IV, or subcutaneous |
| Typical duration | Variable protocols | Varies by condition |
| Administration | Subcutaneous injection | Intranasal, oral, IV, or subcutaneous |
| Timing | Morning With or without food | Morning or as directed With or without food |
| Evidence level | Clinical Trials | FDA Approved |
| Possible side effects |
+3 more
|
+3 more
|
| Research summary | The source highlights early human work with AAV1.CMV.FS344 gene transfer delivered into quadriceps muscle in six men with Becker muscular dystrophy. It reports functional improvement on the 6-minute walk test in several participants, mixed individual responses, biopsy findings consistent with less fibrosis and larger or more normalized fibers, and no serious adverse effects in that small study. The same general gene-transfer strategy is also described as having been studied in sporadic inclusion body myositis. Important limitations remain: the cited human evidence is small, open label, locally delivered, and not yet supported by large placebo-controlled trials. The source distinguishes this research from non-study use of injectable follistatin peptide for physique goals, where controlled human evidence is described as essentially absent. | The source characterizes desmopressin as a long-used approved medicine rather than an experimental peptide. It reports clinical relevance in central diabetes insipidus, nocturnal enuresis, and nocturia through reduced urine production. It also describes hemostatic use because desmopressin can raise von Willebrand factor and factor VIII, with relevance to von Willebrand disease, mild hemophilia A, and some procedure-related contexts. The main safety issue emphasized is dilutional hyponatremia from retained water, with higher concern in young children and older adults according to the supplied source. |
| References | ||
| Full profile | View Details | View Details |
Save this comparison
Keep this research set handy with a free PeptiGuide account.
Save this comparison - free accountTrack your peptide journey
Turn research into a private protocol log when you are ready.
Track your peptide journeyEducational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.